MIT Technology Review Insights and Globant Report: Three quarters of global pharma organizations are piloting or deploying agentic AI
MWN-AI** Summary
A recent report by MIT Technology Review Insights and Globant reveals that a significant transformation is underway in the pharmaceutical sector, with 73% of global pharma organizations currently piloting or deploying agentic AI technologies. This study, involving 250 senior executives across nine countries, indicates a pronounced shift from traditional AI tools to more integrated AI coworkers aimed at enhancing operational efficiencies and patient engagement.
The report highlights several key use cases for agentic AI, including regulatory compliance (51%), data standardization (49%), patient support (46%), and market intelligence (46%). These priorities underscore the industry’s pursuit of new growth avenues, potentially generating between $60 billion and $110 billion annually in economic value. However, deployment challenges persist, particularly in workflow design and compliance, which are noted by 60% and 55% of respondents, respectively.
Crucially, the success of agentic AI hinges on creating strong data foundations. A massive 84% of executives identified data standardization and integration as essential for ensuring AI agents can deliver reliable value. Industry leaders such as Frank Defesche from Salesforce emphasize the need for integrating AI into core business processes rather than treating it as a standalone tool.
Furthermore, the report suggests that agentic AI has the potential to revolutionize medical marketing workflows by facilitating personalized interactions and improving operational agility within the highly regulated pharmaceutical landscape. As organizations like Globant position themselves at the forefront of this digital shift, they advocate for a collaborative approach to harnessing AI's capabilities, not only for efficiency but also for enhancing patient outcomes. The collaborative synergy between human intelligence and AI technology appears to set the stage for a transformative future in healthcare.
MWN-AI** Analysis
The recent report from MIT Technology Review Insights and Globant highlights a compelling shift in the pharmaceutical industry towards agentic AI, with approximately 73% of global pharmaceutical organizations currently engaging in pilot or deployment initiatives. This significant uptake presents critical implications for market analysts and investors seeking to navigate the evolving landscape.
As the pharmaceutical sector anticipates upwards of $100 billion in annual growth opportunities, the early adopters—focusing on priorities such as market intelligence, compliance, and data integration—are poised to gain a competitive edge. This indicates that investments in AI technologies can enhance operational efficiency and regulatory agility, crucial factors in a highly scrutinized industry.
Importantly, the report emphasizes that 84% of respondents prioritize data standardization and integration to capitalize on the potential of AI agents. This underscores a growing need for robust data foundations, suggesting that companies that invest in enhancing their data governance and infrastructure may be better positioned to leverage AI innovations effectively.
Challenges remain, particularly in workflow design and orchestration (60%) and compliance/validation (55%). Companies that can address these hurdles—possibly through partnerships with technology firms like Globant—will likely benefit from accelerated AI deployment and improved market positioning.
Additionally, the insights from industry leaders like Jeff Headd of Johnson & Johnson reinforce the narrative that embracing AI is not merely about job displacement but about augmenting human capabilities. This perspective could encourage organizations to focus on upskilling their workforce alongside AI investments.
In conclusion, investors should consider engaging with firms that are actively pursuing agentic AI strategies. As regulatory compliance and data integration become more critical, companies adept in these areas are poised not only for survival but for significant growth in a transforming pharmaceutical landscape.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
- New global study of 250 pharma leaders shows rapid uptake of agentic AI; early adopters focus on market intelligence, patient support, compliance and data integration.
- As the industry seeks to grasp over $100 billion a year in new growth opportunities, MIT Technology Review Insights claims: "agentic AI promises the next phase of transformation: from AI tool to AI coworker."
MADRID, Spain, Oct. 14, 2025 /PRNewswire/ -- Globant (NYSE: GLOB), a digitally native company that helps organizations thrive in a digital and AI-powered future, has partnered with MIT Technology Review Insights to launch a new report titled, "Transforming Commercial Pharma with Agentic AI." The report reveals that pharmaceutical companies are rapidly adopting AI agents across commercial and medical affairs, finding both strong momentum and clear priorities for the industry.
The report [available to download here] is based on a study conducted by MIT Technology Review Insights, the custom publishing division of MIT Technology Review, backed by the world's foremost technology institution, between May and July 2025. In total, 250 senior executives from the pharmaceuticals, biotech, and bioengineering industries took part, based in nine countries: Canada, US, France, Germany, Italy, Spain, UK, Brazil, and Switzerland.
Key findings from the study
- Nearly three quarters (73%) of respondents are planning, piloting or deploying agentic AI initiatives; some are already in production. Adoption is expected to climb sharply over the next 12–18 months.
- Regulatory compliance (51%), data standardization (49%), patient support (46%), and market intelligence (46%) rank as the highest-priority use cases.
- Workflow design/orchestration (60%) and compliance/validation (55%) are the top challenges to deployment; tech infrastructure (42%) and data governance (38%) follow.
- 84% plan to prioritize data standardization and integration to make agents reliable at scale.
The report includes remarks from Jeff Headd, Vice President of Commercial Data Science for North America, Johnson & Johnson, who commented: "We invested heavily in learning and up-skilling on how to use AI. One of the messages we've emphasized is that AI is not going to take your job, but another human using AI might, so the goal is to become an expert at using it to bring the most out of yourself."
Within its analysis, The MIT Technology Review Insights team notes that generative AI is poised to create between $60 billion and $110 billion a year in economic value for the pharma and medical product industries, stating agentic AI could be the catalyst to kick-start a new phase of transformation for the sector.
To ensure that such promise is delivered, respondents are clear on the need for strong data foundations, with 84% ranking data standardization and integration as a high or medium priority for enabling AI agents to deliver value.
Within the report, Frank Defesche, Senior Vice President and General Manager of Life Sciences at Salesforce, added: "Instead of viewing agentic AI as a standalone, isolated tool, it needs to be embraced as an embedded and inseparable element of core business processes. It's important to build systems that can embed legislation and regulatory documentation directly, and it's essential to establish clear human oversight, specific handoff points where critical decisions must remain in human hands."
These global perspectives present a compelling case for how agentic AI can reshape the commercial and medical functions of the industry, creating new efficiencies, accelerating compliance, and driving more personalized engagement with healthcare professionals and patients.
Joaquín Labado, Healthcare & Life Sciences Managing Director at Globant added: "AI agents can accelerate and innovate across the whole medical-marketing workflow, including research, strategy, execution, and optimization to create relevant and personalized content and services for a specific health care professional to engage with. Rather than create discomfort in a highly regulated industry, it's a chance to set clear agentic rules and guardrails that let us innovate at speed while staying compliant."
Ariel Capone, CEO of Globant's Healthcare & Life Sciences AI Studio, concluded: "At Globant, we are working to ensure that agentic AI becomes a strategic pillar in the future of the pharmaceutical industry. Its value goes far beyond automation: it's about driving a new form of collaboration between people and technology, capable of transforming how the industry innovates, communicates, and improves patients' lives. We believe this is a historic opportunity to build a future for healthcare that is smarter, more agile, and profoundly human."
To learn more about the report, click here.
About Globant
At Globant, we help organizations thrive in a digital and AI-powered future. Our industry-focused solutions combine technology and creativity to accelerate enterprise transformation and design experiences customers love. Through digital reinvention, our subscription-based AI Pods, and Globant Enterprise AI platform, we turn challenges into measurable business results and promised savings into real impact.
- We have more than 30,000 employees and are present in over 35 countries across 5 continents, working for companies like Google, Electronic Arts, and Santander, among others.
- We were named a Worldwide Leader in AI Services (2023) and a Worldwide Leader in Media Consultation, Integration, and Business Operations Cloud Service Providers (2024) by IDC MarketScape report.
- We are the fastest-growing IT brand and the 5th strongest IT brand globally (2024), according to Brand Finance.
- We were featured as a business case study at Harvard, MIT, and Stanford.
- We are active members of The Green Software Foundation (GSF) and the Cybersecurity Tech Accord.
- We are global partners of Open AI, NVIDIA, AWS and Unity bringing world-class technology together to accelerate innovation across industries.
Contact: pr@globant.com
Sign up to get first dibs on press news and updates.
For more information, visit www.globant.com.
SOURCE Globant
FAQ**
How does the adoption of agentic AI within pharmaceutical companies, as reported by MIT Technology Review Insights and Globant S.A. GLOB, impact regulatory compliance and patient support efforts?
What are the top challenges identified by the report regarding the deployment of agentic AI in pharma organizations, and how might Globant S.A. GLOB assist in overcoming them?
Can you elaborate on the expected economic value generated by agentic AI in the pharmaceutical industry, as highlighted in the MIT Technology Review Insights and Globant S.A. GLOB report, and what growth opportunities it may create?
In what ways do the findings of the MIT Technology Review Insights and Globant S.A. GLOB report emphasize the importance of data standardization and integration for the successful implementation of agentic AI in pharmaceuticals?
**MWN-AI FAQ is based on asking OpenAI questions about Globant S.A. (NYSE: GLOB).
NASDAQ: GLOB
GLOB Trading
14.78% G/L:
$38.36 Last:
4,362,923 Volume:
$37.45 Open:
